Idera Pharmaceuticals Inc IDRA shares are trading higher by 43% at $1.60 after it was disclosed in a Form 4 filing the company COO Daniel Soland purchased 50,000 shares of the company stock at an average price of $1.19.
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases.
Idera Pharmaceuticals has developed two distinct proprietary drug-discovery technology platforms: Toll-like receptor and third-generation antisense technology. The Toll-like receptor technology helped the company create synthetic oligonucleotide-based drug candidates.
Idera Pharmaceuticals has a 52-week high of $6.14 and a 52-week low of $0.97
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
